• LAST PRICE
    0.7000
  • TODAY'S CHANGE (%)
    Trending Up0.0100 (1.4493%)
  • Bid / Lots
    0.6901/ 1
  • Ask / Lots
    0.7000/ 11
  • Open / Previous Close
    0.6875 / 0.6900
  • Day Range
    Low 0.6850
    High 0.7246
  • 52 Week Range
    Low 0.5930
    High 2.1000
  • Volume
    157,996
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.69
TimeVolumeCDTX
09:32 ET59200.69
09:33 ET12570.6875
09:35 ET26880.685
09:37 ET28340.6862
09:39 ET60000.7
09:44 ET4200.7246
09:50 ET35460.7001
09:51 ET21000.7001
09:55 ET15040.7001
10:00 ET12000.7
10:02 ET7000.7001
10:04 ET40540.695
10:06 ET125290.7049
10:08 ET7500.6955
10:09 ET121000.7049
10:11 ET29000.7
10:20 ET1990.6905
10:31 ET7630.6974
10:40 ET6000.6974
10:45 ET1000.6974
10:49 ET7000.6902
10:51 ET6600.6903
10:54 ET1000.7047
10:56 ET21000.7047
11:05 ET2300.6966
11:07 ET2100.6965
11:14 ET172090.7048
11:23 ET2000.691
11:30 ET21000.7
11:32 ET32650.7001
11:45 ET4000.7048
11:50 ET21000.7
11:57 ET15000.6912
12:03 ET59820.691
12:17 ET26000.6989
12:19 ET7150.6999
12:21 ET2000.69021
12:44 ET1000.7
12:46 ET133460.7001
01:09 ET1960.6903
01:15 ET1300.7048
01:33 ET4920.695
01:45 ET11000.696
01:47 ET6000.697
01:51 ET98220.695
01:54 ET5000.7048
01:58 ET113190.6861
02:18 ET11510.69
02:20 ET122080.7
02:21 ET7000.688101
02:27 ET5000.6881
02:34 ET13480.7
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCDTX
Cidara Therapeutics Inc
64.1M
-1.8x
---
United StatesPSNL
Personalis Inc
61.8M
-0.5x
---
United StatesBIOQ
Bioqual Inc
64.4M
-140.7x
-25.28%
United StatesATRA
Atara Biotherapeutics Inc
85.7M
-0.3x
---
United StatesTSBX
Turnstone Biologics Corp
52.4M
0.0x
---
United StatesSRNEQ
Sorrento Therapeutics Inc
17.1M
0.0x
---
As of 2024-02-22

Company Information

Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for patients facing serious diseases. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. The Company’s primary focus is using its Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates (DFCs), for the prevention and treatment of serious diseases. This technology couples’ potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Its advanced DFC program is CD388, a long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials.

Contact Information

Headquarters
6310 Nancy Ridge Dr Ste 101SAN DIEGO, CA, United States 92121-3209
Phone
858-752-6170
Fax
302-655-5049

Executives

Independent Chairman of the Board
Daniel Burgess
President, Chief Executive Officer, Director
Jeffrey Stein
Chief Financial Officer, Chief Business Officer
Preetam Shah
Chief Operating Officer, Company Secretary
Shane Ward
Chief Scientific Officer
Leslie Tari

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$64.1M
Revenue (TTM)
$56.5M
Shares Outstanding
90.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.94
EPS
$-0.39
Book Value
$-0.04
P/E Ratio
-1.8x
Price/Sales (TTM)
1.1
Price/Cash Flow (TTM)
---
Operating Margin
-56.02%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.